Claudin18.2在实体瘤中的研究进展

doi:10.3760/cma.j.issn.1007-1245.2024.12.002

摘要/Abstract

摘要：

针对恶性实体瘤，应用手术、放疗、化疗等治疗使患者生存率得到提高，但化疗药物具有选择性低、毒副作用大等缺点。通过研究，靶向药物的疗效展现出了良好的前景。Claudin（CLDN）18.2为不同恶性实体瘤的独特分子，针对CLDN18.2的靶向治疗是最具研究前景的热点。该文针对CLDN18.2的研究进展展开综述。

关键词:

Claudin18.2, 肿瘤, 单克隆抗体, 嵌合抗原受体T细胞治疗, 进展

Abstract:

For malignant solid tumors, we use surgery, radiotherapy, chemotherapy, and other treatments to improve the patients' survival rate, but the application of chemotherapy drugs has the disadvantages of low selectivity and toxicity and side effects. Through research, the efficacy of targeted drugs has shown good prospects. Claudin18.2 is a unique molecule for different malignant solid tumors, and targeted therapy for Claudin18.2 is the most promising research hotspot. This study reviews the research progress of Claudin18.2.

Key words:

Claudin18.2, Tumors, Monoclonal antibody, CAR T cells, Progress

郑晓意林丹霞.

Claudin18.2在实体瘤中的研究进展 [J]. 国际医药卫生导报, 2024, 30(12): 1941-1945.

Zheng Xiaoyi, Lin Danxia.

Research progress of Claudin18.2 in solid tumors [J]. International Medicine and Health Guidance News, 2024, 30(12): 1941-1945.

参考文献

[1] Kyuno D, Takasawa A, Takasawa K,et al.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials[J]. Tissue Barriers,2022,10(1):1967080.DOI: 10.1080/21688370.2021.1967080.
[2] Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions[J]. Nat Rev Mol Cell Biol,2001,2(4):285-293.DOI: 10.1038/35067088.
[3] Sahin U, Koslowski M, Dhaene K,et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development[J]. Clin Cancer Res,2008,14(23):7624-7634.DOI: 10.1158/1078-0432.CCR-08-1547.
[4] Niimi T, Nagashima K, Ward JM,et al. Claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing[J]. Mol Cell Biol,2001,21(21):7380-7390.DOI: 10.1128/MCB.21.21.7380-7390.2001.
[5] Baek JH, Park DJ, Kim GY,et al. Clinical implications of claudin18.2 expression in patients with gastric cancer[J]. Anticancer Res,2019,39(12):6973-6979.DOI: 10.21873/anticanres.13919.
[6] Rohde C, Yamaguchi R, Mukhina S,et al. Comparison of claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma[J]. Jpn J Clin Oncol,2019,49(9):870-876.DOI: 10.1093/jjco/hyz068.
[7] Coati I, Lotz G, Fanelli GN,et al. Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases[J]. Br J Cancer,2019,121(3):257-263.DOI: 10.1038/s41416-019-0508-4.
[8] Wang C, Wang Y, Chen J,et al. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer[J]. BMC Gastroenterol,2023,23(1):283.DOI: 10.1186/s12876-023-02924-y.
[9] Kubota Y, Kawazoe A, Mishima S,et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer[J]. ESMO Open,2023,8(1):100762.DOI: 10.1016/j.esmoop.2022.100762.
[10] Jun KH, Kim JH, Jung JH,et al. Expression of claudin-7 and loss of claudin-18 correlate with poor prognosis in gastric cancer[J]. Int J Surg,2014,12(2):156-162.DOI: 10.1016/j.ijsu.2013.11.022.
[11] Nakayama I, Shinozaki E, Sakata S,et al. Enrichment of CLDN18-ARHGAP fusion gene in gastric cancers in young adults[J]. Cancer Sci,2019,110(4):1352-1363.DOI: 10.1111/cas.13967.
[12] Arnold A, Daum S, von Winterfeld M,et al. Prognostic impact of claudin 18.2 in gastric and esophageal adenocarcinomas[J]. Clin Transl Oncol,2020,22(12):2357-2363.DOI: 10.1007/s12094-020-02380-0.
[13] Pellino A, Brignola S, Riello E,et al. Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas[J]. J Pers Med,2021,11(11):1095.DOI: 10.3390/jpm11111095.
[14] Pereira MA, Ramos MFKP, Dias AR,et al. RhoA, claudin 18, and c-MET in gastric cancer: clinicopathological characteristics and prognostic significance in curative resected patients[J]. Med Sci (Basel),2021,10(1):4.DOI: 10.3390/medsci10010004.
[15] Sanada Y, Oue N, Mitani Y,et al. Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype[J]. J Pathol,2006,208(5):633-642.DOI: 10.1002/path.1922.
[16] Soini Y, Takasawa A, Eskelinen M,et al. Expression of claudins 7 and 18 in pancreatic ductal adenocarcinoma: association with features of differentiation[J]. J Clin Pathol,2012 ,65(5):431-436.DOI: 10.1136/jclinpath- 2011-200400.
[17] Lee JH, Kim KS, Kim TJ,et al. Immunohistochemical analysis of claudin expression in pancreatic cystic tumors[J]. Oncol Rep,2011,25(4):971-978.DOI: 10.3892/or.2011.1132.
[18] Ito T, Kojima T, Yamaguchi H,et al. Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methylation in human pancreatic cancer cells[J]. J Cell Biochem,2011,112(7):1761-1772.DOI: 10.1002/jcb.23095.
[19] Wöll S, Schlitter AM, Dhaene K,et al. Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms[J]. Int J Cancer,2014,134(3):731-739.DOI: 10.1002/ijc.28400.
[20] Türeci Ӧ, Mitnacht-Kraus R, Wöll S,et al. Characterization of zolbetuximab in pancreatic cancer models[J]. Oncoimmunology,2018,8(1):e1523096.DOI: 10.1080/2162402X.2018.1523096.
[21] Shinozaki A, Shibahara J, Noda N,et al. Claudin-18 in biliary neoplasms. Its significance in the classification of intrahepatic cholangiocarcinoma[J]. Virchows Arch,2011 ,459(1):73-80.DOI: 10.1007/s00428-011-1092-z.
[22] Keira Y, Takasawa A, Murata M,et al. An immunohistochemical marker panel including claudin-18, maspin, and p53 improves diagnostic accuracy of bile duct neoplasms in surgical and presurgical biopsy specimens[J]. Virchows Arch,2015,466(3):265-277.DOI: 10.1007/s00428-014-1705-4.
[23] Espinoza JA, Riquelme I, Sagredo EA,et al. Mucin 5B, carbonic anhydrase 9 and claudin 18 are potential theranostic markers of gallbladder carcinoma[J]. Histopathology,2019 ,74(4):597-607.DOI: 10.1111/his.13797.
[24] Tokumitsu T, Sato Y, Yamashita A,et al. Immunocytochemistry for claudin-18 and maspin in biliary brushing cytology increases the accuracy of diagnosing pancreatobiliary malignancies[J]. Cytopathology,2017,28(2):116-121.DOI: 10.1111/cyt.12368.
[25] Takasawa K, Takasawa A, Osanai M,et al. Claudin-18 coupled with EGFR/ERK signaling contributes to the malignant potentials of bile duct cancer[J]. Cancer Lett,2017,403:66-73. DOI: 10.1016/j.canlet.2017.05.033.
[26] Liu J, Yang H, Yin D,et al. Expression and prognostic analysis of CLDN18 and Claudin18.2 in lung adenocarcinoma[J]. Pathol Res Pract,2022,238:154068.DOI: 10.1016/j.prp.2022.154068.
[27] Wang Y, Gao Y, Zhang Z,et al. Claudin18.2 expression in pulmonary mucinous adenocarcinoma[J]. J Cancer Res Clin Oncol,2023,149(14):12923-12929.DOI: 10.1007/s00432-023-05150-x.
[28] Türeci O, Sahin U, Schulze-Bergkamen H, et al. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study[J]. Ann Oncol,2019,30(9):1487-1495.DOI: 10.1093/annonc/mdz199.
[29] Sahin U , Albatran S E , Hozaeel W ,et al.IMAB362 plus zoledronic acid (ZA) and interleukin-2 (IL-2) in patients (pts) with advanced gastroesophageal cancer (GEC): clinical activity and safety data from the PILOT phase I trial[J].Journal of Clinical Oncology, 2015, 33(15):e15079-e15079.DOI:10.1200/jco.2015.33.15_suppl.e15079.
[30] Sahin U, Türeci Ö, Manikhas G,et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma[J]. Ann Oncol,2021,32(5):609-619.DOI: 10.1016/j.annonc.2021.02.005.
[31] Klempner SJ, Lee KW, Metges JP,et al.Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2[J].Journal of Clinical Oncology,2021,39(15):e16063-e16063.DOI:10.1200/JCO.2021.39.15_suppl.e16063.
[32] Zhan X, Wang B, Li Z,et al.Phase I trial of claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma[J].Journal of Clinical Oncology, 2019, 37(15):2509-2509.DOI:10.1200/JCO.2019.37.15_suppl.2509.
[33] Qi C, Gong J, Li J,et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results[J]. Nat Med,2022,28(6):1189-1198.DOI: 10.1038/s41591-022-01800-8.
[34] Shah MA, Shitara K, Ajani JA,et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial[J]. Nat Med, 2023,29(8):2133-2141.DOI: 10.1038/s41591-023-02465-7.
[35] Shitara K, Kawazoe A, Hirakawa A,et al. Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma[J]. Cancer Sci,2023,114(4):1606-1615.DOI: 10.1111/cas.15684.
[36] Shitara K, Lordick F, Bang YJ,et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial[J]. Lancet,2023,401(10389):1655-1668.DOI: 10.1016/S0140-6736(23)00620-7.